论文部分内容阅读
目的探讨倍他乐克注射液联合西地兰对房颤快速心室率伴心衰的疗效及安全性。方法对房颤伴心衰的患者,先给以西地兰0.2 mg稀释后缓慢静脉注射,观测半小时,如心率仍>100次/m in、血压≥100/60 mm Hg以上的患者,予倍他乐克注射液10 mg稀释后缓慢静脉注射1 h,当心率≤60次/m in、血压<90/60 mm Hg时停止;静脉注射倍他乐克前、后,观察症状、体征、心率、血压、肺部啰音、无创血流动力学和BNP、ANP等指标。结果用倍他乐克后心室率平均减少了23.73次/m in(P<0.01),收缩压降低5.69 mm Hg(P<0.05),舒张压降低5.26 mm Hg(P<0.05),使用倍他乐克前后SI、SV、VI、SVR、ISVR、LVET有明显改变(P<0.05),BNP、ANP无显著变化。结论倍他乐克注射液联合西地兰治疗快室率房颤伴心衰是有效和安全的。
Objective To investigate the efficacy and safety of Betaloc injection combined with cedilanid in the treatment of rapid ventricular rate and heart failure in patients with atrial fibrillation. Methods Atrial fibrillation patients with heart failure, first given cedilanid 0.2 mg diluted intravenous injection, observed for half an hour, such as heart rate is still> 100 / m in, blood pressure ≥ 100/60 mm Hg or more patients, Talc injection 10 mg diluted slowly intravenous injection 1 h, when the heart rate ≤ 60 times / m in, blood pressure <90/60 mm Hg stop; intravenous Betaloc, before and after observation of symptoms, signs, heart rate , Blood pressure, pulmonary rales, non-invasive hemodynamics and BNP, ANP and other indicators. Results Ventricular rate decreased by 23.73 times / min (P <0.01), systolic pressure decreased by 5.69 mm Hg (P <0.05) and diastolic pressure decreased by 5.26 mm Hg (P <0.05) There were significant changes in SI, SV, VI, SVR, ISVR and LVET before and after the Lok (P <0.05), but no significant changes in BNP and ANP. Conclusion Betaloc injection combined with cedilanid in the treatment of fast ventricular rate of atrial fibrillation with heart failure is effective and safe.